Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > DNA flow cytometry of canine mammary tumors: comparative aspects with human breast tumors
Publication

Publications

DNA flow cytometry of canine mammary tumors: comparative aspects with human breast tumors

Title
DNA flow cytometry of canine mammary tumors: comparative aspects with human breast tumors
Type
Article in International Scientific Journal
Year
2007
Authors
Cassali, GD
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Salvador, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Freitas, C
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Dutra, AP
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Fernando Schmitt
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Journal
Vol. 59
Pages: 1163-1168
ISSN: 0102-0935
Other information
Authenticus ID: P-004-6X5
Abstract (EN): Flow cytometric analysis of DNA content was performed on 28 samples of canine mammary tumors. Nine of them were benign and 19 were malignant. All benign tumors and 11 malignant tumors (57.9%) were diploid (P<0.05). Form the aneuploid tumors, five (26.3%) were hyperdiploid, one (5.3%) hypodiploid, one (5.3%) near triploid and one (5.3%) multiploid. The analysis of the expression of the markers PR and CD31 revealed a significant difference between diploid and aneuploid tumors (P<0.05). The immunoreactivity of PR was higher in diploid tumors, while the immunoreactivity of CD31 was stronger in aneuploid tumors. No difference between the markers MIB-1, c-erbB2, p53 and Cyclin D1 was observed (P>0.05). Using the flow cytometry analysis and immunohistochemistry, it was found a close relationship between aneuploidy and malignant character of neoplasias, progesterone receptor (PR) negative immunostaining and higher microvases density. No correlation between DNA content and S phase or immunoreactivity for the markers MIB-1, p53, c-erbB2 and Cyclin D1 was observed.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 6
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

Tartrate-resistant acid phosphatase as a biomarker of bone turnover in dog (2011)
Article in International Scientific Journal
Sousa, CP; Nery, F; Azevedo, JT; Viegas, CA; Gomes, ME; Dias, IR
Serum total and bone alkaline phosphatase and tartrate-resistant acid phosphatase activities for the assessment of bone fracture healing in dogs (2011)
Article in International Scientific Journal
Sousa, C; Abreu, H; Viegas, C; Azevedo, J; Rui Reis; Gomes, M; Dias, I
Protocol for the anatomopathological examination of canine mammary tumors (2003)
Article in International Scientific Journal
Ferreira, E; Bregunci, GC; Fernando Schmitt; Cassali, GD
Pleomorphic lobular carcinoma of the canine mammary gland: histopathologic and immunohistochemical features (2002)
Article in International Scientific Journal
Cassali, GD; Gartner, F; Fernando Schmitt
Invasive micropapillary carcinoma of the dog mammary gland. A case report (2002)
Article in International Scientific Journal
Cassali, GD; Serakides, R; Gartner, F; Fernando Schmitt

See all (12)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-06 at 20:02:07 | Privacy Policy | Personal Data Protection Policy | Whistleblowing